January 15, 2012 -- North American Veterinary Conference, Orlando, Fla. – As one of the top three fastest growing veterinary pharmaceutical companies – and the 9th largest veterinary company in the world – Ceva is set to continue making its North American presence known. The company continues momentum from 2011 and heads into 2012 with recent Canadian acquisitions, increased support for the veterinary profession with targeted sponsorships, unique promotions and a consumer advertising campaign.

Last October, Ceva increased its global footprint by acquiring Vetech Laboratories, Inc. and CentaurVA Animal Health, both located in Guelph, Ontario. Vetech produces live coccidiosis vaccines under the trade name Immucox®. The Centaur acquisition further expands Ceva’s companion animal operations in North America; its range of products includes nutraceuticals, joint therapies and infection-control products.

In the United States, Ceva is launching the new year with several programs to help drive pet owners to veterinary clinics. As a leading cosponsor of the AAFP’s Cat-Friendly Practice Initiative, the company is helping underwrite campaign tools and promote strategies for the optimal level of care for cats. This follows last year’s partnership to produce an AAFP brochure to help cat owners select cat carriers that reduce stress.

Ceva is also planning an extensive consumer outreach campaign using both traditional advertising venues and new social media programs. The consumer advertising campaign will include leading cat and dog publications. The messaging will educate pet owners about Ceva’s products and how they can help keep companion animals safe and healthy, while also driving awareness of the essential role of veterinarians in pet care.Reinforcing Ceva’s mission to support the bond between animals and humans, the company has joined with Leader Dogs for the Blind to sponsor the training of “Ceva, the Future Leader Dog.” Ceva is a Labrador puppy who will undergo formal training before being matched to a person who is blind. Ceva will also wear a new Ceva Adaptil™ Collar with Braille lettering to help with her training.

“We are looking forward to our continued growth and development of our partnerships in the veterinary profession. At the same time, our values guide what we do every day. While we grow, we remain committed to maintaining our entrepreneurial spirit, our commitment to innovation, and our solidarity as a team. It’s an exciting time at Ceva,” said Craig Wallace, Chief Executive Officer and North America Zone Director of Ceva Animal Health.

About Ceva Animal Health: Ceva’s key companion animal products include the Vectra® line of parasiticides, AdaptilTM (formerly D.A.P.) and Feliway® pheromone behavior aids and Senilife® neuroprotection for aging pets. Ceva Biomune’s key poultry products include CEVAC® Transmune IBD, Vectormune® FP and Vectormune® HVT. Ceva Biomune Campus and the North America Zone headquarters are both located in Lenexa, Kansas. Visit www.ceva.us.

About Ceva Santé Animale: Ceva’s parent company is a global veterinary health company focused on the research, development, production and marketing of pharmaceutical products and vaccines for pets, livestock, swine and poultry. Its headquarters is in Libourne, France. Visit www.ceva.com.

For more information, please contact Carolyn Gilliland at carolyn.gilliland[at]ceva.com or 913.945.4448.

###